Printer Friendly

VITRO DIAGNOSTICS -- NATIONAL INSTITUTES OF HEALTH AWARDS VITRO BLANKET PURCHASE AGREEMENT

 LITTLETON, Colo., March 8 /PRNewswire/ -- Vitro Diagnostics Inc. (OTC: Bulletin Board: VODG) announced today it was awarded a blanket purchase agreement from the National Cancer Institutes (NCI) of Bethesda, Md. NCI is a research group, that studies all aspects of cancer, within the National Institutes of Health.
 The agreement is for purchase of highly purified carcinoembryonic antigen (CEA), which is used for various research projects studying possible therapeutic and diagnostic uses of CEA. CEA is one of the better known tumor markers.
 Dr. Jim Musick, Vitro's chief operating officer, said the agreement "indicates the fundamental quality of Vitro's purified antigens. This group tested CEA manufactured by many companies. Vitro's CEA outperformed the competitors in all respects. It was especially effective in a cell-proliferation assay, because the proprietary technology used by Vitro eliminated a contaminate that was common in the CEA produced by other suppliers."
 Vitro's CEA is also substantially free of non-cross-reacting antigen, another common contaminate of CEA. Musick said that this specification allows for "wide-spread use of Vitro's CEA at the NCI. We are able to provide our customers with high-purity antigens that meet criterion levels of specific contaminates. The use of proprietary purification technology, at high levels of overall efficiency, allows Vitro to provide its customers competitive pricing, while maintaining attractive profit margins."
 Littleton-based Vitro Diagnostics produces and markets biological products used in diagnostic kits to test for causes of sterility and to diagnose and monitor the progression of cancer. It is one of the few manufacturers in the world that specializes in the purification of human pituitary hormones.
 -0- 3/8/93
 /CONTACT: Roger Hurst of Vitro Diagnostics, 303-794-2000/
 (VODG)


CO: Vitro Diagnostics Inc. ST: Colorado IN: MTC SU:

MC -- DV001 -- 3838 03/08/93 09:04 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1993
Words:291
Previous Article:FORD TRUCKS SET SALES PACE IN FEBRUARY
Next Article:ROYAL CARIBBEAN SIGNS CONTRACTS FOR CONSTRUCTION OF NEW SHIPS
Topics:


Related Articles
VITRO DIAGNOSTICS, INC. Major Shareholder Sells Shares.
Research Scientist Joins Vitro's Staff.
Vitro Diagnostics, Inc. 1998 Sales Increase 89%; 1999 First Quarter Sales Increase 335%.
Director of The Center for the Study of Reproductive Biology and Disease at University of California, San Diego Joins Advisory Board.
Vitro Diagnostics, Inc. Reports Six Month Results.
Chief of the Department of Reproductive Endocrinology At Colorado Permanente Medical Group Joins Advisory Board.
Vitro Diagnostics, Inc. Semifinalist for ATP Grant.
Vitro Diagnostics, Inc. Awarded NIH Research Grant.
Vitro Announces Progress in Grant-Winning Cell Immortalization Research.
Prominent Hormone Research Scientist Joins Vitro's Advisory Board.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters